ESPR - Esperion Therapeutics Quarterly EPS earnings growth

Corporate emblem and logo of Esperion Corp (ESPR)

Esperion Therapeutics (ESPR) revenues are based on the stable sales of hypercholesterolemia treatments. The quarterly EPS growth rate clearly demonstrates the pace of this expansion, where the value 51.00 serves as the baseline indicator of current efficiency. Strategic partnerships with pharma behemoths and clinics drive this success. Growth is supported by a mission-driven culture, the recruitment of rare lipid experts, and a flexible stock option system.

Esperion (ESPR) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 07/25/2026

Esperion (ESPR) - metric breakdowns and financial figures

- market value and analyst target forecast:
Fundamental company valuation:Esperion Therapeutics Inc - ESPR
Finished products of esperion.com

The investment attractiveness of Esperion Therapeutics (ESPR) depends on scaling sales of cholesterol therapy drugs and expanding insurance coverage. This metric measures quarterly net earnings per share dynamics, revealing the impact of cost inflation on real margins. By analyzing the quarterly EPS growth rate, an investor can filter out random market noise. Such precision allows for an assessment of the business's resilience to logistics costs. Purchasing the asset at the indicator's peak creates a risk of significant capital correction.

Who Esperion Therapeutics competes with

Regeneron Pharmaceuticals (REGN) - Year-over-year earnings per share growth for the last twelve months|IRTC: Year-over-year earnings per share growth rate for the last twelve months|LNTH (Lantheus Holdings) - Quarterly EPS earnings growth|Quarterly EPS earnings growth mineralystx.com|Year-over-year earnings per share growth for the last twelve months HeartFlow Inc (HTFL)|KMTS (Kestra Medical Technologies, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AMRN (Amarin Pharma)|Year-over-year earnings per share growth rate for the last twelve months AVR (Anteris Technologies Ltd)|Tenaya Therapeutics, Inc. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months CVRx, Inc. CVRX|MIST (Milestone Pharmaceuticals Inc.) - Year-over-year net earnings per share growth for the last 12 months|Cardiol Therapeutics Inc - Year-over-year earnings per one share growth for the last 12 months|BEAT (HeartBeam Corporation) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Tenax Therapeutics Inc|Quarterly EPS earnings growth ADGM|BioCardia, Inc. - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth VTAK (Catheter Precision Inc)|ABIO - Year-over-year net earnings per share growth for the last 12 months|Acasti Pharma - Quarterly EPS earnings growth|AVTE - Quarterly EPS earnings growth|VERV (vervetx.com) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share trend for the last twelve months WINT (Windtree Therapeutics Inc.)